FIA
RETA

FNY Investment Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

FNY Investment Advisers’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$1K – 755
2023
Q1 		$1K Buy
+15
New +$880 ﹤0.01% 532

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FNY Investment Advisers's RETA Position: Q1 2019 in Review

FNY Investment Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2019, closing a stake of 194 shares — an estimated $10K sold.

FNY Investment Advisers first reported a position in RETA in Q3 2018 and held it in 2 quarters. The position peaked at $65K in Q3 2018. 157 funds tracked by Wall St. Rank hold RETA as of Q1 2019.

  • FNY Investment Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 194 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2019, an estimated $10K.
  • FNY Investment Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $65K in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2019.

Based on FNY Investment Advisers's 13F filing for Q1 2019, filed 17 Apr 2019.